PSMA/FOLH1 Fc Chimera Protein, Human,specification,price,image-Bio-Equip in China

Product Detail
Company Profile

Product Specification

Species	Human
Synonyms	GIG27, FOLH, NAALAD1, PSM, NAALADase I, GCPII, FGCP
Accession	Q04609-1
Amino Acid Sequence	Lys44-Ala750 , with N-terminal Fc
Expression System	HEK293
Molecular Weight	110-140kDa (Reducing)
Purity	>95% by SDS-PAGE & SEC-HPLC
Endotoxin	<0.1EU/μg
Conjugation	Unconjugated
Tag	Human IgG1 Fc
Physical Appearance	Lyophilized Powder
Storage Buffer	PBS, pH7.4, 5% trehalose
Reconstitution	Reconstitute at 0.1-1 mg/ml according to the size in ultrapure water after rapid centrifugation.
Stability & Storage	· 12 months from date of receipt, lyophilized powder stored at -20 to -80℃. · 3 months, -20 to -80℃ under sterile conditions after reconstitution. · 1 week, 2 to 8℃ under sterile conditions after reconstitution. · Please avoid repeated freeze-thaw cycles.
Reference	Su S L. et al. (1995) Alternatively spliced variants of prostate-specific membrane antigen RNA: ratio of expression as a potential measurement of progression. Cancer Res. 55: 1441-1443. O'Keefe D S. et al. (1998) Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochim Biophys Acta. 1443: 113-127.

Background

Prostate-Specific Membrane Antigen (PSMA) is a transmembrane protein that is consistently found in prostatic tissues. Its expression is notably elevated in various malignancies, with prostate cancer exhibiting particularly high levels. In nearly all cases of prostate adenocarcinoma, PSMA is expressed in the majority of both primary and metastatic lesions.
Immunohistochemical analysis has shown that PSMA expression intensifies in patients with dedifferentiated, metastatic, or hormone-refractory tumors. The level of PSMA expression has been correlated with the prognosis of the disease, offering significant predictive value for patient outcomes.